| Range Cancer Therapeutics ETF | ||||||||
| Schedule of Investments | ||||||||
| November 30, 2024 (Unaudited) | ||||||||
| COMMON STOCKS - 99.4% | Shares | Value | ||||||
Biotechnology - 80.4%(a) | ||||||||
2seventy bio, Inc. (b) | 34,816 | $ | 138,916 | |||||
Acrivon Therapeutics, Inc. (b) | 20,348 | 154,238 | ||||||
Adicet Bio, Inc. (b) | 111,642 | 126,155 | ||||||
Agenus, Inc. (b) | 27,543 | 94,197 | ||||||
Allogene Therapeutics, Inc. (b) | 60,675 | 150,474 | ||||||
Apollomics, Inc. (b) | 12,591 | 112,061 | ||||||
Arcellx, Inc. (b) | 2,175 | 191,552 | ||||||
Arcus Biosciences, Inc. (b) | 9,909 | 152,995 | ||||||
Aura Biosciences, Inc. (b) | 16,797 | 156,380 | ||||||
Autolus Therapeutics PLC - ADR (b) | 41,866 | 138,995 | ||||||
Bicycle Therapeutics PLC - ADR (b) | 6,707 | 136,823 | ||||||
Biomea Fusion, Inc. (b) | 20,985 | 151,931 | ||||||
BioNTech SE - ADR (b) | 1,356 | 160,537 | ||||||
Blueprint Medicines Corporation (b) | 1,940 | 186,977 | ||||||
Caribou Biosciences, Inc. (b) | 82,494 | 180,662 | ||||||
Compass Therapeutics, Inc. (b) | 97,931 | 159,628 | ||||||
Cullinan Therapeutics, Inc. (b) | 9,891 | 133,034 | ||||||
Day One Biopharmaceuticals, Inc. (b) | 12,286 | 171,144 | ||||||
Erasca, Inc. (b) | 59,384 | 169,838 | ||||||
Exelixis, Inc. (b) | 6,096 | 222,260 | ||||||
Fate Therapeutics, Inc. (b) | 42,289 | 134,056 | ||||||
Genelux Corporation (b) | 65,930 | 177,352 | ||||||
Genmab AS - ADR (b) | 6,300 | 135,450 | ||||||
Geron Corporation (b) | 38,321 | 157,883 | ||||||
Ideaya Biosciences, Inc. (b) | 4,547 | 124,406 | ||||||
IGM Biosciences, Inc. (b) | 10,572 | 106,143 | ||||||
Immatics NV (b) | 13,155 | 109,450 | ||||||
ImmunityBio, Inc. (b) | 47,984 | 241,839 | ||||||
Immunocore Holdings PLC - ADR (b) | 5,075 | 166,156 | ||||||
Inhibrx Biosciences, Inc. (b) | 9,608 | 146,618 | ||||||
Innate Pharma SA - ADR (b) | 77,350 | 119,119 | ||||||
Iovance Biotherapeutics, Inc. (b) | 17,071 | 159,102 | ||||||
iTeos Therapeutics, Inc. (b) | 13,840 | 118,332 | ||||||
Janux Therapeutics, Inc. (b) | 3,357 | 151,770 | ||||||
Karyopharm Therapeutics, Inc. (b) | 218,791 | 184,900 | ||||||
Kymera Therapeutics, Inc. (b) | 3,454 | 161,820 | ||||||
Legend Biotech Corporation - ADR (b) | 3,265 | 137,359 | ||||||
MacroGenics, Inc. (b) | 48,823 | 175,275 | ||||||
Mersana Therapeutics, Inc. (b) | 85,006 | 193,814 | ||||||
Monte Rosa Therapeutics, Inc. (b) | 29,798 | 308,707 | ||||||
Nurix Therapeutics, Inc. (b) | 6,583 | 145,550 | ||||||
Nuvalent, Inc. - Class A (b) | 1,493 | 144,343 | ||||||
Nuvation Bio, Inc. (b) | 54,548 | 158,189 | ||||||
Precigen, Inc. (b) | 167,496 | 156,123 | ||||||
Prelude Therapeutics, Inc. (b) | 64,409 | 67,629 | ||||||
RAPT Therapeutics, Inc. (b) | 89,076 | 112,236 | ||||||
Recursion Pharmaceuticals, Inc. - Class A (b) | 50,761 | 358,881 | ||||||
Regeneron Pharmaceuticals, Inc. (b) | 145 | 108,782 | ||||||
Relay Therapeutics, Inc. (b) | 20,649 | 97,050 | ||||||
Replimune Group, Inc. (b) | 16,010 | 225,421 | ||||||
REVOLUTION Medicines, Inc. (b) | 3,760 | 217,516 | ||||||
SpringWorks Therapeutics, Inc. (b) | 4,709 | 195,329 | ||||||
Summit Therapeutics, Inc. (b) | 5,681 | 104,871 | ||||||
Sutro Biopharma, Inc. (b) | 45,260 | 119,939 | ||||||
Syndax Pharmaceuticals, Inc. (b) | 9,201 | 153,841 | ||||||
Tango Therapeutics, Inc. (b) | 17,426 | 68,658 | ||||||
Tyra Biosciences, Inc. (b) | 8,311 | 130,316 | ||||||
Vor BioPharma, Inc. (b) | 165,805 | 137,966 | ||||||
Xencor, Inc. (b) | 7,918 | 202,701 | ||||||
Zentalis Pharmaceuticals, Inc. (b) | 45,506 | 164,277 | ||||||
Zymeworks, Inc. (b) | 13,386 | 188,609 | ||||||
9,556,575 | ||||||||
| Chemicals - 2.0% | ||||||||
Ginkgo Bioworks Holdings, Inc. (b) | 26,880 | 233,856 | ||||||
| Health Care Technology - 1.6% | ||||||||
Schrodinger, Inc. (b) | 8,432 | 190,310 | ||||||
| Pharmaceuticals - 15.4% | ||||||||
Arvinas, Inc. (b) | 6,659 | 177,929 | ||||||
| Bristol-Myers Squibb Company | 3,350 | 198,387 | ||||||
Enliven Therapeutics, Inc. (b) | 7,483 | 182,436 | ||||||
Foghorn Therapeutics, Inc. (b) | 18,085 | 144,499 | ||||||
HUTCHMED China, Ltd. - ADR (b) | 10,131 | 171,720 | ||||||
Immuneering Corporation - Class A (b) | 58,349 | 121,949 | ||||||
Kura Oncology, Inc. (b) | 8,024 | 88,585 | ||||||
Lyell Immunopharma, Inc. (b) | 135,050 | 127,636 | ||||||
| Merck & Company, Inc. | 1,420 | 144,329 | ||||||
Merus NV (b) | 3,336 | 149,586 | ||||||
Repare Therapeutics, Inc. (b) | 50,441 | 165,447 | ||||||
Y-mAbs Therapeutics, Inc. (b) | 12,872 | 153,434 | ||||||
1,825,937 | ||||||||
TOTAL COMMON STOCKS (Cost $15,987,402) | 11,806,678 | |||||||
| SHORT-TERM INVESTMENTS - 0.7% | Value | |||||||
| Money Market Funds - 0.7% | Shares | |||||||
First American Government Obligations Fund - Class X, 4.56% (c) | 87,152 | 87,152 | ||||||
TOTAL SHORT-TERM INVESTMENTS (Cost $87,152) | 87,152 | |||||||
TOTAL INVESTMENTS - 100.1% (Cost $16,074,554) | 11,893,830 | |||||||
| Liabilities in Excess of Other Assets - (0.1)% | (7,250 | ) | ||||||
| TOTAL NET ASSETS - 100.0% | $ | 11,886,580 | ||||||
| two | – | % | ||||||
| Percentages are stated as a percent of net assets. | – | % | ||||||
| ADR - American Depositary Receipt |
| AS - Aksjeselskap |
| NV - Naamloze Vennootschap |
| PLC - Public Limited Company |
| SA - Sociedad Anónima |
| SE - Societas Europeae |
| (a) | To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors. |
| (b) | Non-income producing security. |
| (c) | The rate shown represents the 7-day annualized effective yield as of November 30, 2024. |
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Investments: | ||||||||||||||||
| Common Stocks | $ | 11,806,678 | $ | – | $ | – | $ | 11,806,678 | ||||||||
| Money Market Funds | 87,152 | – | – | 87,152 | ||||||||||||
| Total Investments | $ | 11,893,830 | $ | – | $ | – | $ | 11,893,830 | ||||||||
| Refer to the Schedule of Investments for further disaggregation of investment categories. | ||||||||||||||||
